Association between metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.

Rev Endocr Metab DisordJun 11, 2026 (epub)
Clinical ResearchGastroenterologyNephrologyOpen access

André O Soares, Davi A C Loli, Gustavo R Carvalho et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD) in adults without CKD at baseline. The analysis of 20 studies revealed a risk ratio for CKD incidence of 1.29 for MAFLD, 1.16 for MASLD, and 1.25 for NAFLD compared to controls, indicating a significant association between steatotic liver disease and CKD.

Key findings

  • The risk ratio for CKD incidence in MAFLD was 1.29 (1.18-1.40) compared to controls.
  • The risk ratio for CKD incidence in MASLD was 1.16 (1.12-1.19) compared to controls.
  • The risk ratio for CKD incidence in NAFLD was 1.25 (1.14-1.36) compared to controls.

Why it matters

Understanding the association between steatotic liver disease and chronic kidney disease is crucial for clinicians, as it may influence monitoring and management strategies for patients with liver conditions, potentially improving patient outcomes.

Source

PubMed · PMID 42270864Free full text on PubMed Central

Published in Rev Endocr Metab Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.